Variables | 1999 | 2013 | Age group in 2013 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total (n = 4007) | Total (n = 6295) | 50–59 years (n = 1077) | 60–79 years (n = 3211) | 80+ years (n = 2077) | |||||||
n (%) or Median [P25; P75] | n (%) or Median [P25; P75] | n (%) or Median [P25; P75] | Statin use cat.a % | Statin use ref. cat.b % | n (%) or Median [P25; P75] | Statin use cat.a % | Statin use ref. cat.b % | n (%) or Median [P25; P75] | Statin use cat.a % | Statin use ref. cat.b % | |
Statin use, n (%) | 295 (7.4) | 2477 (39.3) | 330 (32.8) | Â | Â | 1614 (50.3) | Â | Â | 533 (25.7) | Â | Â |
Baseline characteristics | |||||||||||
 Age (years), median [IQR] | 73 [66; 79] | 74 [64; 82] | 55 [52; 57] |  |  | 70 [65; 75] |  |  | 85 [82; 89] |  |  |
 Women, n (%) | 1839 (45.9) | 2871 (45.6) | 448 (44.5) | 24.1*** | 39.7 | 1280 (39.9) | 41.6*** | 56.0 | 1143 (55) | 20.4*** | 32.1 |
 LDL measurement, n (%) | 1559 (38.9) | 2405 (38.2) | 421 (42.0) | 23.3*** | 39.6 | 1040 (32.4) | 38.8*** | 55.8 | 944 (45.5) | 14.6*** | 34.9 |
Type of CVD history | |||||||||||
 MI, n (%) | 848 (21.2) | 1507 (23.9) | 331 (32.9) | 36.3* | 31.1 | 786 (24.5) | 59.0*** | 47.4 | 390 (18.8) | 31.0** | 24.4 |
 Stroke, n (%) | 831 (20.7) | 1496 (23.8) | 248 (24.6) | 29.8 | 33.7 | 672 (20.9) | 46.3** | 51.3 | 576 (27.7) | 20.5*** | 27.6 |
 TIA, n (%) | 631 (15.7) | 963 (15.3) | 67 (6.7) | 41.8 | 32.1 | 414 (12.9) | 49.3 | 50.4 | 482 (23.2) | 21.8** | 26.8 |
 IHD without angina, n (%) | 754 (18.8) | 1147 (18.2) | 144 (14.3) | 42.4** | 31.2 | 648 (20.2) | 61.3*** | 47.5 | 355 (17.1) | 33.2*** | 24.1 |
 IHD with angina, n (%) | 1582 (39.5) | 1809 (28.7) | 173 (17.2) | 46.8*** | 29.9 | 938 (29.2) | 54.1** | 48.7 | 698 (33.6) | 27.5 | 24.7 |
 PAD, n (%) | 1011 (25.2) | 1669 (26.5) | 242 (24.0) | 27.3** | 34.5 | 873 (27.2) | 45.9** | 51.9 | 554 (26.7) | 27.4 | 25.0 |
Comorbidities | |||||||||||
 Atrial fibrillation, n (%) | 430 (10.7) | 870 (13.8) | 24 (2.4) | 45.8 | 32.5 | 359 (11.2) | 53.8 | 49.8 | 487 (23.4) | 21.1** | 27.0 |
 Hypercholesterolemia, n (%) | 1040 (26.0) | 2075 (33.0) | 292 (29.0) | 50.7*** | 25.5 | 1134 (35.3) | 60.6*** | 44.6 | 649 (31.2) | 34.2*** | 21.8 |
Hypertension, n (%) | 1396 (34.8) | 2772 (44.0) | 344 (34.2) | 36.6* | 30.8 | 1422 (44.3) | 51.7 | 49.1 | 1006 (48.4) | 24.8 | 26.5 |
Mental disorder, n (%) | 625 (15.6) | 1310 (20.8) | 289 (28.7) | 32.5 | 32.9 | 627 (19.5) | 45.1** | 51.5 | 394 (19.0) | 17.5*** | 27.6 |
Co-medications | |||||||||||
Aspirin and antihypertensive agents | |||||||||||
 Aspirin + RAS and  Non-RAS | 75 (1.9) | 707 (11.2) | 88 (8.7) | Ref cat |  | 458 (14.3) | Ref cat |  | 161 (7.8) | Ref cat |  |
 Aspirin + RAS or  Non-RAS, n (%) | 295 (7.4) | 1464 (23.3) | 171 (17.0) | 73.5 | 80.7 | 959 (29.9) | 73.7** | 81.0 | 334 (16.1) | 63.0** | 70.8 |
 Aspirin alone, n (%) | 68 (1.7) | 226 (3.6) | 45 (4.5) | 68.9 | 80.7 | 147 (4.6) | 58.5*** | 81.0 | 34 (1.6) | 44.1*** | 70.8 |
 RAS or Non-RAS and no aspirin, n (%) | 702 (17.5) | 1808 (28.7) | 256 (25.4) | 38.7*** | 80.7 | 1014 (31.6) | 60.4*** | 81.0 | 538 (25.9) | 44.8*** | 70.8 |
 None of these 3 categories, n (%) | 2942 (73.4) | 2797 (44.4) | 535 (53.1) | 12.7*** | 80.7 | 1091 (34.0) | 16.1*** | 81.0 | 1171 (56.4) | 4.6*** | 70.8 |
 Other lipid-lowering medication | 73 (4.3) | 237 (3.8) | 37 (3.7) | 48.6** | 32.2 | 164 (5.1) | 43.3* | 50.6 | 36 (1.7) | 30.6 | 25.6 |
Charlson comorbidity index | |||||||||||
 mCCI indexc, median [IQR] | 5 [3; 6] | 5 [4; 7] | 3 [2; 4] |  |  | 5 [4; 6] |  |  | 7 [6; 8] |  |  |
 MI/ IHD w/o angina, n (%) | 1395 (34.8) | 2364 (37.6) | 442 (43.9) | 36.4** | 29.9 | 1269 (39.5) | 59.3*** | 44.3 | 653 (31.4) | 32.3*** | 22.6 |
 Heart failure, n (%) | 364 (9.1) | 500 (7.9) | 20 (2.0) | 55.0** | 32.3 | 156 (4.9) | 59.6** | 49.8 | 324 (15.6) | 19.1** | 26.9 |
 PAD, n (%) | 1011 (25.2) | 1669 (26.5) | 242 (24.0) | 27.3** | 34.5 | 873 (27.2) | 45.9** | 51.9 | 554 (26.7) | 27.4 | 25.0 |
 TIA/stroke, n (%) | 1333 (33.3) | 2283 (36.3) | 305 (30.3) | 31.8 | 33.2 | 1014 (31.6) | 46.6** | 51.9 | 964 (46.4) | 21.1*** | 29.6 |
Dementia, n (%) | 94 (2.3) | 301 (4.8) | 17 (1.7) | 23.5 | 32.9 | 87 (2.7) | 40.2* | 50.5 | 197 (9.5) | 14.7*** | 26.8 |
COPD/asthma, n (%) | 579 (14.4) | 1580 (25.1) | 276 (27.4) | 31.9 | 33.1 | 862 (26.8) | 48.4 | 51.0 | 442 (21.3) | 24.7 | 25.9 |
GI ulcer, n (%) | 471 (11.8) | 647 (10.3) | 65 (6.5) | 30.8 | 32.9 | 331 (10.3) | 49.5 | 50.3 | 251 (12.1) | 21.9 | 26.2 |
Liver disease, n (%) | 110 (2.7) | 361 (5.7) | 52 (5.2) | 40.4 | 32.4 | 200 (6.2) | 48.0 | 50.4 | 109 (5.2) | 20.2 | 26.0 |
Diabetes mellitus, n (%) | 644 (16.1) | 1587 (25.2) | 235 (23.3) | 38.7** | 31.0 | 855 (26.6) | 58.9*** | 47.1 | 497 (23.9) | 27.4 | 25.1 |
Paralysis, n (%) | 122 (3.0) | 141 (2.2) | 18 (1.8) | 55.6** | 32.4 | 65 (2.0) | 43.1 | 50.4 | 58 (2.8) | 15.5* | 26.0 |
Cancer, n (%) | 382 (9.5) | 1207 (19.2) | 191 (19.0) | 20.9*** | 35.5 | 631 (19.7) | 43.3*** | 52.0 | 385 (18.5) | 23.4 | 26.2 |
Leukaemia, n (%) | 9 (0.2) | 40 (0.6) | 10 (1.0) | 20.0 | 32.9 | 15 (0.5) | 46.7 | 50.3 | 15 (0.7) | 33.3 | 25.6 |
Hodgkin’s lymphoma, n (%) | 12 (0.3) | 44 (0.7) | 6 (0.6) | 16.7 | 32.9 | 27 (0.8) | 40.7 | 50.3 | 11 (0.5) | 36.4 | 25.6 |
HIV-infection/ AIDS, n (%) | NA | NA | NA | Â | Â | Â | Â | Â | Â | Â | Â |
Renal insufficiencyd, n (%) | |||||||||||
 Yes vs no | 468 (11.7) | 665 (10.6) | 14 (1.4) | 50.0 | 37.7 | 192 (6.0) | 49.5 | 54.6 | 459 (22.1) | 25.3** | 31.9 |
 Not measured vs measured | 755 (18.8) | 970 (15.4) | 214 (21.3) | 13.6*** | 38.0 | 372 (11.6) | 19.6*** | 54.3 | 384 (18.5) | 6.0*** | 30.1 |